
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The occurrence of seizures in children can generate tremendous levels of anxiety for children, parents, and pediatricians alike. Allaying these concerns and providing the right treatment rests on a systematic approach.






